Chronic exposure of colorectal cancer cells to bevacizumab promotes compensatory pathways that mediate tumour cell migration

BACKGROUND: Bevacizumab (Bev), a monoclonal antibody to vascular endothelial growth factor (VEGF), is used in combination with chemotherapy for the treatment of metastatic colorectal cancer (CRC). The effects of Bev on angiogenesis have been well described, but the direct effect of Bev on tumour cel...

Descripción completa

Detalles Bibliográficos
Autores principales: Fan, F, Samuel, S, Gaur, P, Lu, J, Dallas, N A, Xia, L, Bose, D, Ramachandran, V, Ellis, L M
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2011
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3078594/
https://www.ncbi.nlm.nih.gov/pubmed/21407219
http://dx.doi.org/10.1038/bjc.2011.81

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3078594/
https://www.ncbi.nlm.nih.gov/pubmed/21407219
http://dx.doi.org/10.1038/bjc.2011.81

Ejemplares similares